Konstantinos Savvatis, MD, PH D, a,b,c Christoffer Rasmus Vissing, MD, d,e Lori Klouvi, f Anca Florian, MD, PH D, g Mehjabin Rahman, BS C, MSC ,c Anthony Béhin, MD,h Abdallah Fayssoil, MD, PHD, i,j Marion Masingue, MD,h Tanya Stojkovic, MD, h Henri Marc Bécane, MD,h Nawal Berber, P HD, h Fanny Mochel, MD, PHD, k,l Denis Duboc, MD, P HD, h,m,n Bertrand Fontaine, MD, P HD, o Bjørg Krett, MD, d Caroline Stalens, PHD, f Julie Lejeune, PHD, f Robert D.S. Pitceathly, MD, PHD, p Luis Lopes, MD, PH D, a,c Malika Saadi, MD,m Thomas Gossios, MD, PHD, q Vincent Procaccio, MD, P HD, r,s Marco Spinazzi, MD,s,t Céline Tard, MD, PHD, u,v Pascal De Groote, MD,w,x Claire-Marie Dhaenens, MD,y Claire Douillard, MD, z Andoni Echaniz-Laguna, MD, M HD, aa,bb,cc Ros Quinlivan, MBBS, MD, p Michael G. Hanna, MBC H B, MD,p Ali Yilmaz, MD, PH D, g John Vissing, MD, PHD, d Pascal Laforêt, MD, PHD, x,dd,ee Perry Elliott, MD, P HD, a,c Karim Wahbi, MD, P HD
doi : 10.1016/j.jacc.2022.08.716
Volume 80, Issue 15, 11 October 2022, Pages 1421-1430
Patients with mitochondrial diseases are at risk of heart failure (HF) and arrhythmic major adverse cardiac events (MACE).
Alessandro Di Toro, MD,a Mario Urtis, BME, a,b Nupoor Narula, MD,a,c Lorenzo Giuliani, MS, a Maurizia Grasso, PHD, a Michele Pasotti, MD,d Carlo Pellegrini, MD,e,f Alessandra Serio, MD,a Andrea Pilotto, MS, a Elena Antoniazzi, MD,g Teresa Rampino, MD,h Lorenzo Magrassi, MD,i Adele Valentini, MD, j Anna Cavallini, MD, k Laura Scelsi, MD, l Stefano Ghio, MD, l Massimo Abelli, MD,m Iacopo Olivotto, MD, n Maurizio Porcu, MD, o Antonello Gavazzi, MD,p Takahide Kodama, MD, q Eloisa Arbustini, MD
doi : 10.1016/j.jacc.2022.04.067
Volume 80, Issue 15, 11 October 2022, Pages 1431-1443
The heart is commonly involved in maternally inherited mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome caused by the MT-TL1 m.3243A>G mutation of the mitochondrial DNA. Heart transplantation (HTx) is controversial and has rarely been performed with conflicting results.
Stephanie M. Ware, MD, P HD
doi : 10.1016/j.jacc.2022.08.719
Volume 80, Issue 15, 11 October 2022, Pages 1444-1446
Fernando de Frutos, MD, a,b,c Juan Pablo Ochoa, MD, P HD, a,c,d Marina Navarro-Peñalver, MD, b,c,e Annette Baas, MD, PHD, f Jesper Vandborg Bjerre, MD,g Esther Zorio, MD, P HD, b,h Irene Méndez, MD, b,i,j Rebeca Lorca, MD, k,l,m Job A.J. Verdonschot, MD, PH D, n Pablo Elpidio GarcÃa-Granja, MD, P HD, b,o Zofia Bilinska, MD, P HD, p Diane Fatkin, MD, q,r,s M. Eugenia Fuentes-Cañamero, MD, t José M. GarcÃa-Pinilla, MD, P HD, b,u MarÃa I. GarcÃa-Ã�lvarez, MD, v,w Francesca Girolami, PHD, x Roberto Barriales-Villa, MD, PHD, b,y Carles DÃez-López, MD, z,aa Luis R. Lopes, MD,bb,cc Karim Wahbi, MD, dd,ee Ana GarcÃa-Ã�lvarez, MD, PHD, b,d,ff Ibon RodrÃguez-Sánchez, MD, gg Javier Rekondo-Olaetxea, MD,hh José F. RodrÃguez-Palomares, MD, PHD, b,ii MarÃa Gallego-Delgado, MD, PH D, b,jj,kk Benjamin Meder, MD, PH D, ll,mm Milos Kubanek, MD, PH D, nn Frederikke G. Hansen, MD, oo MarÃa Alejandra Restrepo-Córdoba, MD, pp Julián Palomino-Doza, MD, b,qq Luis Ruiz-Guerrero, MD,rr Georgia Sarquella-Brugada, MD, PH D, c,ss,tt,uu Alberto José Perez-Perez, MD, vv Francisco José Bermúdez-Jiménez, MD, PHD, ww,xx Tomas Ripoll-Vera, MD, PHD, yy Torsten Bloch Rasmussen, MD, PHD, zz Mark Jansen, MD, f Maria Sabater-Molina, PHD, b,e,aaa Perry M. Elliot, MD, bb,cc Pablo Garcia-Pavia, MD, P HD, a,b,c,d,bbb on behalf of the European Genetic Cardiomyopathies Initiative Investigators*
doi : 10.1016/j.jacc.2022.07.023
Volume 80, Issue 15, 11 October 2022, Pages 1447-1461
Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described.
David E. Lanfear, MD, MS, a Nosheen Reza, MDb
doi : 10.1016/j.jacc.2022.08.749
Volume 80, Issue 15, 11 October 2022, Pages 1462-1464
Veronica Giorgione, MD, a,b Asma Khalil, MD, a,b Jamie O’Driscoll, P HD, c,d Basky Thilaganathan, MD, P HD
doi : 10.1016/j.jacc.2022.07.028
Volume 80, Issue 15, 11 October 2022, Pages 1465-1476
Joan E. Briller, MD
Andrzej Januszewicz, MD, PHD, a, * Paolo Mulatero, MD, b, * Piotr Dobrowolski, MD, PHD, a Silvia Monticone, MD, PHD, b Patricia Van der Niepen, MD, P HD, c Pantelis Sarafidis, MD, MS C, P HD, d Martin Reincke, MD, e Emrush Rexhaj, MD, f Graeme Eisenhofer, PH D, g Magdalena Januszewicz, MD, PH D, a,h Alexandros Kasiakogias, MD, P HD, i,j Reinhold Kreutz, MD, P HD, k Jacques W.M. Lenders, MD, PH D, g,l Maria Lorenza Muiesan, MD, PHD, m Alexandre Persu, MD, PH D, n Enrico Agabiti-Rosei, MD, PH D, o Rodrigo Soria, MD,f Mateusz Spiewak, MD, PHD, p Aleksander Prejbisz, MD, PHD, a,y Franz H. Messerli, MD
doi : 10.1016/j.jacc.2022.08.714
Volume 80, Issue 15, 11 October 2022, Pages 1480-1497
Several forms of secondary hypertension carry a high risk of cardiac morbidity and mortality. Evaluation of cardiac phenotypes in secondary hypertension provides a unique opportunity to study underlying hormonal and biochemical mechanisms affecting the heart.
Joyee Basu, BMBCh, MA, PhD Gherardo Finocchiaro, MD, PhD Shruti Jayakumar, BSc, MBBS Julia Schönfeld, MSc Hamish MacLachlan, MBChB, MSc Chris Miles, BSc, MBChB, PhD Gemma Parry-Williams, MBChB Maite Tome, MD, PhD Michael Papadakis, MBBS, MD *Sanjay Sharma, BSc, MBChB, MD
doi : 10.1016/j.jacc.2022.08.715
Volume 80, Issue 15, 11 October 2022, Pages 1498-1500
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟